BridgeBio Pharma BBIO has become a harder stock to judge after its sharp rare-disease run. Attruby is ramping quickly, yet the valuation already assumes a good deal of future success.
The key question is not whether the company has momentum. It does. The question is whether that momentum can keep outpacing the risks tied to product concentration, launch execution and spending.
BBIO Sales Momentum Makes the Bull Case
Attruby gives the bull case its strongest support. The drug generated $362.4 million in U.S. sales in 2025, its first full year on the market, and nearly $181 million in the first quarter of 2026.
First-quarter revenues reached $194.5 million, above the Zacks Consensus Estimate of $179.8 million, as Attruby uptake continued across patient types and provider segments. That launch strength matters because ATTR-CM remains underdiagnosed, leaving room for diagnosed patient growth.
BridgeBio is also preparing for three potential U.S. product launches over the next 12 months. BBP-418 is under FDA review for LGMD2I/R9, encaleret has been submitted for ADH1 and infigratinib is expected to be filed in achondroplasia in the third quarter of 2026.
That pipeline gives BridgeBio a chance to evolve from an Attruby-led company into a broader rare disease platform. Pfizer PFE remains relevant because its Vyndaqel family is the established competitor in ATTR-CM, keeping BridgeBio’s market-share gains central to the story.
Why BridgeBio Still Looks Execution Heavy
The caution case starts with concentration. Attruby is BridgeBio’s only approved product, making near-term revenues highly dependent on one commercial asset.
That leaves little room for disruption from safety concerns, access hurdles or slower-than-expected prescribing. Even a strong product can underperform if reimbursement, patient identification or physician education lag in rare disease markets.
The same execution burden applies to the pipeline. BBP-418 and encaleret could become first therapies for their target indications, while infigratinib may benefit from oral dosing, but approval alone would not guarantee rapid uptake.
BioMarin Pharmaceutical BMRN and Ascendis Pharma ASND illustrate the competitive backdrop in achondroplasia, where BridgeBio would need to position infigratinib against existing injectable options if approved.
BridgeBio Pharma, Inc. Price and Consensus
BridgeBio Pharma, Inc. price-consensus-chart | BridgeBio Pharma, Inc. Quote
Valuation Leaves BBIO Little Room to Slip
Valuation is the clearest reason for patience. BBIO trades at 12.3X forward 12-month enterprise value to sales, far above 2.7X for the Zacks sub-industry, 2.7X for the sector and 4.9X for the S&P 500.
That premium can be justified only if Attruby continues to scale and the next wave of approvals arrives on schedule. The stock has gained 69.4% over the past 12 months, which means investors are already paying for a sizable portion of the growth narrative.
BridgeBio Earnings Show Growth and Cost Pressure
The latest quarter showed why the debate remains balanced. Revenues rose 66.8% year over year, driven by Attruby, but BridgeBio reported a loss of 84 cents per share, wider than the Zacks Consensus Estimate of a loss of 70 cents.
Operating costs climbed to $300.5 million from $221 million a year earlier. Selling, general and administrative expenses rose to $163.9 million as the company supported Attruby's commercialization and prepared for late-stage launches.
Research and development expenses also increased, reaching $126.6 million. The growth is real, but it is not yet translating cleanly into bottom-line improvement.
Why BBIO Merits a Wait-and-See View
The bottom line is that BBIO still looks more like a stock to monitor than chase aggressively after its run. Attruby’s launch supports the bull case, but the premium valuation leaves limited room for launch delays, cost pressure or slower market-share gains.
The stock’s balanced profile fits a Zacks Rank #3 (Hold) discussion rather than a high-conviction buy view. A Zacks Rank #3 indicates a more neutral near-term earnings revision picture, which lines up with the mix of strong sales momentum and execution-heavy risk. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BridgeBio Pharma, Inc. (BBIO): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report
Ascendis Pharma A/S (ASND): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).